|
|
|
|
|
|
By Fritz Röder, GMP Compliance Adviser | Drug manufacturers face stringent requirements when using gas that comes into direct contact with the product. This guide discusses operation, maintenance, and monitoring of gas systems. | |
|
|
|
| How AI Streamlines Cell Therapy Manufacturing | Article | By Geoffrey Stephens, AiCella, Inc, and Michelle Duquette, Invetech | Harnessing the power of AI, biotherapeutic developers can better understand cellular processes and outcomes, paving the way for more personalized and effective treatments for patients. |
|
|
|
|
| Human Platelet Lysate (hPL) Improves Expansion Of MSCs | Application Note | FUJIFILM Biosciences | Learn how human platelet lysate significantly improves mesenchymal stromal/stem cell expansion and eliminates the need for plate coating, boosting yield without altering cell phenotype. |
|
|
| Why Manual Bottle Filling Puts Biomanufacturers At Risk | Article | Single Use Support | Manual bottle filling can introduce significant risks, impacting accuracy, sterility, and compliance. Grasp how automation can improve product quality, enhance patient safety, and increase efficiency. |
|
|
| The Growing Role Of MSCs In Regenerative Medicine | Article | Corning Life Sciences | Mesenchymal stem cells (MSCs) show great promise in regenerative medicine, but scaling their production for clinical use is a key challenge that requires careful optimization and planning. |
|
|
| Detect Ultra-Rare Variants In cfDNA From Liquid Biopsy Samples | Application Note | By Zhong Wu, Krishna Amin, et al., QIAGEN | Liquid biopsy, powered by next-generation sequencing, is transforming precision oncology to offer real-time, non-invasive insights into tumor genetics, which revolutionizes how we monitor and manage cancer. |
|
|
|
| How To Successfully Isolate Your T Cells | Application Note | Cytiva | Explore the results of a study focusing on the early stages of the CAR T cell workflow, specifically the initial washing of leukapheresis followed by the isolation of T cells. |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Advancing the Future of Cell & Gene Therapy | This 11-12 November, Cell 2025 unites 1,000+ leading experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development timelines. Gain practical strategies across cell culture, therapy development, and CGT manufacturing, and hear from world-renowned leaders Bobby Gaspar (CEO, Orchard Therapeutics), Christof Von Kalle, (Director & BIH Chair, Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now |
|
|
Connect With Cell & Gene: |
|
|
|